A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy

Abdel-Wahab, R.; Varadhachary, G.R.; Bhosale, P.R.; Wang, X.; Fogelman, D.R.; Shroff, R.T.; Overman, M.J.; Wolff, R.A.; Javle, M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J. Hematol. Oncol., 2018, 11(1), 71.
[http://dx.doi.org/10.1186/s13045-018-0616-2] [PMID: 29843755]

Agero, A.L.; Dusza, S.W.; Benvenuto-Andrade, C.; Busam, K.J.; Myskowski, P.; Halpern, A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol., 2006, 55(4), 657-670.
[http://dx.doi.org/10.1016/j.jaad.2005.10.010] [PMID: 17010747]

Aghevlian, S.; Cai, Z.; Lu, Y.; Hedley, D.W.; Winnik, M.A.; Reilly, R.M. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NRG mice with panitumumab modified with metal-chelating polymers complexed to ¹⁷⁷Lu. Mol. Pharm., 2019, 16(2), 768-778.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b01040] [PMID: 30589553]

Andrén-Sandberg, A. Pancreatic cancer: Chemotherapy and radiotherapy. N. Am. J. Med. Sci., 2011, 3(1), 1-12.
[http://dx.doi.org/10.4297/najms.2011.31] [PMID: 22540056]

Arora, A.K. Erlotinib-induced hepatotoxicity-clinical presentation and successful management: A case report. J. Clin. Exp. Hepatol., 2011, 1(1), 38-40.
[http://dx.doi.org/10.1016/S0973-6883(11)60112-6] [PMID: 25755309]

Arteaga, C.L. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist, 2002, 7(Suppl. 4), 31-39.
[http://dx.doi.org/10.1634/theoncologist.7-suppl_4-31] [PMID: 12202786]

Basti, S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs., 2007, 30(4)(Suppl. 1), S10-S16.
[http://dx.doi.org/10.1097/01.NCC.0000281759.23823.82] [PMID: 17666986]

Berry, W.; Algar, E.; Kumar, B.; Desmond, C.; Swan, M.; Jenkins, B.J.; Croagh, D. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Int. J. Cancer, 2017, 140(10), 2331-2343.
[http://dx.doi.org/10.1002/ijc.30648] [PMID: 28198009]

Boram, H.; Kim, H.S.; Choi, D.R.; Shim, B.Y.; Lee, K.H.; Kim, J.W.; Kim, J.H.; Kim, J.H.; Kim, H.Y.; Song, H.; Park, C.K.; Moon, S.H.; Kim, J.H.; Jeon, J.Y.; Lee, J.W.; Zang, D.Y. Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer. J. Clin. Oncol., 2017, 35(15)(Suppl.), e15778-e15778.

Burris, H.; Storniolo, A.M. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur. J. Cancer, 1997, 33(Suppl. 1), S18-S22.
[http://dx.doi.org/10.1016/S0959-8049(96)00324-3] [PMID: 9166095]

Burris, H.A., III; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol., 1997, 15(6), 2403-2413.
[http://dx.doi.org/10.1200/JCO.1997.15.6.2403] [PMID: 9196156]

Burtness, B.; Powell, M.; Catalano, P.; Berlin, J.; Liles, D.K.; Chapman, A.E.; Mitchell, E.; Benson, A.B. Randomized phase II trial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer: An eastern cooperative oncology group study. Am. J. Clin. Oncol., 2016, 39(4), 340-345.
[http://dx.doi.org/10.1097/COC.0000000000000068] [PMID: 24685886]

Capasso, M.; Franceschi, M.; Rodriguez-Castro, K.I.; Crafa, P.; Cambie, G.; Miraglia, C.; Barchi, A.; Nouvenne, A.; Leandro, G.; Meschi, T. De’ Angelis G.L.; Mario D.F. Epidemiology and risk factors of pancreatic cancer. Acta Biomed., 2018, 89, 141-146.

Cascinu, S.; Berardi, R.; Salvagni, S.; Beretta, G.D.; Catalano, V.; Pucci, F.; Sobrero, A.; Tagliaferri, P.; Labianca, R.; Scartozzi, M.; Crocicchio, F.; Mari, E.; Ardizzoni, A. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br. J. Cancer, 2008, 98(1), 71-76.
[http://dx.doi.org/10.1038/sj.bjc.6604121] [PMID: 18059397]

Cook, N.F.K.; Moore, M. Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointest. Cancer, 2014, 2014, 4.

Cunningham, D.; Chau, I.; Stocken, D.D.; Valle, J.W.; Smith, D.; Steward, W.; Harper, P.G.; Dunn, J.; Tudur-Smith, C.; West, J.; Falk, S.; Crellin, A.; Adab, F.; Thompson, J.; Leonard, P.; Ostrowski, J.; Eatock, M.; Scheithauer, W.; Herrmann, R.; Neoptolemos, J.P. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2009, 27(33), 5513-5518.
[http://dx.doi.org/10.1200/JCO.2009.24.2446] [PMID: 19858379]

Czito, B.G.; Willett, C.G.; Bendell, J.C.; Morse, M.A.; Tyler, D.S.; Fernando, N.H.; Mantyh, C.R.; Blobe, G.C.; Honeycutt, W.; Yu, D.; Clary, B.M.; Pappas, T.N.; Ludwig, K.A.; Hurwitz, H.I. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol., 2006, 24(4), 656-662.
[http://dx.doi.org/10.1200/JCO.2005.04.1749] [PMID: 16446337]

Dorjee, P.; Long, Z.W. A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer. Cancer Biol. Ther., 2018, 19(6), 497-506.
[http://dx.doi.org/10.1080/15384047.2018.1433503] [PMID: 29658816]

Feliu, J.; Borrega, P.; León, A.; López-Gómez, L.; López, M.; Castro, J.; Belda-Iniesta, C.; Barriuso, J.; Martínez, V.; González-Barón, M. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother. Pharmacol., 2011, 67(1), 215-221.
[http://dx.doi.org/10.1007/s00280-010-1472-0] [PMID: 20927525]

Fiore, M.; Trodella, L.; Valeri, S.; Borzomati, D.; Floreno, B.; Ippolito, E.; Trecca, P.; Trodella, L.E.; D’Angelillo, R.M.; Ramella, S.; Coppola, R. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: Feasibility and efficacy in locally advanced pancreatic head cancer. Radiat. Oncol., 2015, 10, 255.
[http://dx.doi.org/10.1186/s13014-015-0564-8] [PMID: 26670587]

Fitzmaurice, C.; Akinyemiju, T.F.; Al Lami, F.H.; Alam, T.; Alizadeh-Navaei, R.; Allen, C.; Alsharif, U.; Alvis-Guzman, N.; Amini, E.; Anderson, B.O.; Aremu, O.; Artaman, A.; Asgedom, S.W.; Assadi, R.; Atey, T.M.; Avila-Burgos, L.; Awasthi, A.; Ba Saleem, H.O.; Barac, A.; Bennett, J.R.; Bensenor, I.M.; Bhakta, N.; Brenner, H.; Cahuana-Hurtado, L.; Castañeda-Orjuela, C.A.; Catalá-López, F.; Choi, J.J.; Christopher, D.J.; Chung, S.C.; Curado, M.P.; Dandona, L.; Dandona, R. das Neves, J.; Dey, S.; Dharmaratne, S.D.; Doku, D.T.; Driscoll, T.R.; Dubey, M.; Ebrahimi, H.; Edessa, D.; El-Khatib, Z.; Endries, A.Y.; Fischer, F.; Force, L.M.; Foreman, K.J.; Gebrehiwot, S.W.; Gopalani, S.V.; Grosso, G.; Gupta, R.; Gyawali, B.; Hamadeh, R.R.; Hamidi, S.; Harvey, J.; Hassen, H.Y.; Hay, R.J.; Hay, S.I.; Heibati, B.; Hiluf, M.K.; Horita, N.; Hosgood, H.D.; Ilesanmi, O.S.; Innos, K.; Islami, F.; Jakovljevic, M.B.; Johnson, S.C.; Jonas, J.B.; Kasaeian, A.; Kassa, T.D.; Khader, Y.S.; Khan, E.A.; Khan, G.; Khang, Y.H.; Khosravi, M.H.; Khubchandani, J.; Kopec, J.A.; Kumar, G.A.; Kutz, M.; Lad, D.P.; Lafranconi, A.; Lan, Q.; Legesse, Y.; Leigh, J.; Linn, S.; Lunevicius, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Mantovani, L.G.; McMahon, B.J.; Meier, T.; Melaku, Y.A.; Melku, M.; Memiah, P.; Mendoza, W.; Meretoja, T.J.; Mezgebe, H.B.; Miller, T.R.; Mohammed, S.; Mokdad, A.H.; Moosazadeh, M.; Moraga, P.; Mousavi, S.M.; Nangia, V.; Nguyen, C.T.; Nong, V.M.; Ogbo, F.A.; Olagunju, A.T.; Pa, M.; Park, E.K.; Patel, T.; Pereira, D.M.; Pishgar, F.; Postma, M.J.; Pourmalek, F.; Qorbani, M.; Rafay, A.; Rawaf, S.; Rawaf, D.L.; Roshandel, G.; Safiri, S.; Salimzadeh, H.; Sanabria, J.R.; Santric Milicevic, M.M.; Sartorius, B.; Satpathy, M.; Sepanlou, S.G.; Shackelford, K.A.; Shaikh, M.A.; Sharif-Alhoseini, M.; She, J.; Shin, M.J.; Shiue, I.; Shrime, M.G.; Sinke, A.H.; Sisay, M.; Sligar, A.; Sufiyan, M.B.; Sykes, B.L.; Tabarés-Seisdedos, R.; Tessema, G.A.; Topor-Madry, R.; Tran, T.T.; Tran, B.X.; Ukwaja, K.N.; Vlassov, V.V.; Vollset, S.E.; Weiderpass, E.; Williams, H.C.; Yimer, N.B.; Yonemoto, N.; Younis, M.Z.; Murray, C.J.L.; Naghavi, M. Global burden of disease cancer collaboration. global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol., 2018, 4(11), 1553-1568.
[http://dx.doi.org/10.1001/jamaoncol.2018.2706] [PMID: 29860482]

Fountzilas, C.; Chhatrala, R.; Khushalani, N.; Tan, W.; LeVea, C.; Hutson, A.; Tucker, C.; Ma, W.W.; Warren, G.; Boland, P.; Iyer, R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother. Pharmacol., 2017, 80(3), 497-505.
[http://dx.doi.org/10.1007/s00280-017-3375-9] [PMID: 28702772]

Fountzilas, G.; Bobos, M.; Kalogera-Fountzila, A.; Xiros, N.; Murray, S.; Linardou, H.; Karayannopoulou, G.; Koutras, A.K.; Bafaloukos, D.; Samantas, E.; Christodoulou, C.; Economopoulos, T.; Kalogeras, K.T.; Kosmidis, P. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest., 2008, 26(8), 784-793.
[http://dx.doi.org/10.1080/07357900801918611] [PMID: 18798073]

Friess, H.; Wang, L.; Zhu, Z.; Gerber, R.; Schröder, M.; Fukuda, A.; Zimmermann, A.; Korc, M.; Büchler, M.W. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann. Surg., 1999, 230(6), 767-774.
[http://dx.doi.org/10.1097/00000658-199912000-00005] [PMID: 10615931]

Furuse, J.; Gemma, A.; Ichikawa, W.; Okusaka, T.; Seki, A.; Ishii, T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn. J. Clin. Oncol., 2017, 47(9), 832-839.
[http://dx.doi.org/10.1093/jjco/hyx075] [PMID: 28541474]

Furuya, T.; Shimada, J.; Okada, S.; Tsunezuka, H.; Kato, D.; Inoue, M. Successful treatment with afatinib for pancreatic metastasis of lung adenocarcinoma: A case report. J. Thorac. Dis., 2017, 9(10), E890-E893.
[http://dx.doi.org/10.21037/jtd.2017.09.123] [PMID: 29268429]

Gao, C.; Wu, X.; Yan, Y.; Meng, L.; Shan, D.; Li, Y.; Han, B. Sensitization of radiation or gemcitabine-based chemoradiation therapeutic effect by nimotuzumab in pancreatic cancer cells. Technol. Cancer Res. Treat., 2016, 15(3), 446-452.
[http://dx.doi.org/10.1177/1533034615585209] [PMID: 25987640]

Haas, M.; Boeck, S.H.; Waldschmidt, D.; Reinacher-Schick, A.; Freiberg-Richter, J.; Seufferlein, T.; Kanzler, S.; Mahlberg, R.; Siveke, J.T.; Heinemann, V. ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors-An explorative randomized phase II trial. J. Clin. Oncol., 2015, 33, TPS4150-TPS4150.
[http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps4150]

Haas, M.; Siveke, J.T.; Schenk, M.; Lerch, M.M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T.J.; Kruger, S.; Westphalen, C.B.; Held, S.; Heinemann, V.; Boeck, S. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Eur. J. Cancer, 2018, 94, 95-103.
[http://dx.doi.org/10.1016/j.ejca.2018.02.008] [PMID: 29549862]

Haas, M.; Waldschmidt, D.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.J.C.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Held, S.; Westphalen, C.B.; Kruger, S.; Boeck, S.; Heinemann, V. 719PGemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 2018, 29(Suppl. 8), 82-102.
[http://dx.doi.org/10.1093/annonc/mdy282.102]

Halfdanarson, T.R.; Foster, N.R.; Kim, G.P.; Meyers, J.P.; Smyrk, T.C.; McCullough, A.E.; Ames, M.M.; Jaffe, J.P.; Alberts, S.R. A Phase II randomized trial of panitumumab, erlotinib, and gemcitabine versus erlotinib and gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist, 2019, 24(5), 589-e160.
[http://dx.doi.org/10.1634/theoncologist.2018-0878] [PMID: 30679315]

Herrmann, R.; Bodoky, G.; Ruhstaller, T.; Glimelius, B.; Bajetta, E.; Schüller, J.; Saletti, P.; Bauer, J.; Figer, A.; Pestalozzi, B.; Köhne, C.H.; Mingrone, W.; Stemmer, S.M.; Tàmas, K.; Kornek, G.V.; Koeberle, D.; Cina, S.; Bernhard, J.; Dietrich, D.; Scheithauer, W. Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol., 2007, 25(16), 2212-2217.
[http://dx.doi.org/10.1200/JCO.2006.09.0886] [PMID: 17538165]

Hidalgo, M. Erlotinib: preclinical investigations. Oncology (Williston Park), 2003, 17(11)(Suppl. 12), 11-16.
[PMID: 14682118]

Holcmann, M.; Sibilia, M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol. Cell. Oncol., 2015, 2(4)e1004969
[http://dx.doi.org/10.1080/23723556.2015.1004969] [PMID: 27308503]

Huguet, F.; Fernet, M.; Giocanti, N.; Favaudon, V.; Larsen, A.K. Afatinib, an irreversible EGFR family inhibitor, shows activity toward pancreatic cancer cells, alone and in combination with radiotherapy, independent of KRAS status. Target. Oncol., 2016, 11(3), 371-381.
[http://dx.doi.org/10.1007/s11523-015-0403-8] [PMID: 26668065]

Idachaba, S.; Dada, O.; Abimbola, O.; Olayinka, O.; Uma, A.; Olunu, E.; Fakoya, A.O.J. A review of pancreatic cancer: Epidemiology, genetics, screening, and management. Open Access Maced. J. Med. Sci., 2019, 7(4), 663-671.
[http://dx.doi.org/10.3889/oamjms.2019.104] [PMID: 30894932]

Ignatiadis, M.; Polyzos, A.; Stathopoulos, G.P.; Tselepatiotis, E.; Christophylakis, C.; Kalbakis, K.; Vamvakas, L.; Kotsakis, A.; Potamianou, A.; Georgoulias, V. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 2006, 71(3-4), 159-163.
[http://dx.doi.org/10.1159/000106064] [PMID: 17646699]

Ioannou, N.; Dalgleish, A.G.; Seddon, A.M.; Mackintosh, D.; Guertler, U.; Solca, F.; Modjtahedi, H. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br. J. Cancer, 2011, 105(10), 1554-1562.
[http://dx.doi.org/10.1038/bjc.2011.396] [PMID: 21970876]

Irigoyen, A.; Gallego, J.; Guillén Ponce, C.; Vera, R.; Iranzo, V.; Ales, I.; Arévalo, S.; Pisa, A.; Martín, M.; Salud, A.; Falcó, E.; Sáenz, A.; Manzano Mozo, J.L.; Pulido, G.; Martínez Galán, J.; Pazo-Cid, R.; Rivera, F.; García García, T.; Serra, O.; Fernández Parra, E.M.; Hurtado, A.; Gómez Reina, M.J.; López Gomez, L.J.; Martínez Ortega, E.; Benavides, M.; Aranda, E. Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. Eur. J. Cancer, 2017, 75, 73-82.
[http://dx.doi.org/10.1016/j.ejca.2016.12.032] [PMID: 28222309]

Jhappan, C1 SC; Harkins, RN.; Fausto, N.; Smith, GH.; Merlino, GT. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 1990, 15, 1137-1146.

Jones, J.; Takeda, A.; Tan, S.C.; Cooper, K.; Loveman, E.; Clegg, A. Gemcitabine for the treatment of metastatic breast cancer. Health Technol. Assess., 2009, 13(Suppl. 2), 1-7.
[http://dx.doi.org/10.3310/hta13suppl2/01] [PMID: 19804683]

Kim, G.P.; Foster, N.R.; Salim, M.; Flynn, P.J.; Jr, D.F.M.; Zon, R.; Mowat, R.B.; McCullough, A.; Meyers, J.P.; Alberts, S.R. Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma. J. Clin. Oncol., 2011, 29, 238-238.
[http://dx.doi.org/10.1200/jco.2011.29.4_suppl.238]

Knickelbein, K.; Zhang, L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis., 2015, 2(1), 4-12.
[http://dx.doi.org/10.1016/j.gendis.2014.10.002] [PMID: 25815366]

Ko, A.H.; Bekaii-Saab, T.; Van Ziffle, J.; Mirzoeva, O.M.; Joseph, N.M.; Talasaz, A.; Kuhn, P.; Tempero, M.A.; Collisson, E.A.; Kelley, R.K.; Venook, A.P.; Dito, E.; Ong, A.; Ziyeh, S.; Courtin, R.; Linetskaya, R.; Tahiri, S.; Korn, W.M. A multicenter, open-label phase ii clinical trial of combined mek plus egfr inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clin. Cancer Res., 2016, 22(1), 61-68.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0979] [PMID: 26251290]

Li, Q.; Zhang, L.; Li, X.; Yan, H.; Yang, L.; Li, Y.; Li, T.; Wang, J.; Cao, B. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer, 2016, 16(1), 910.
[http://dx.doi.org/10.1186/s12885-016-2889-6] [PMID: 27871278]

Li, S.; Schmitz, K.R.; Jeffrey, P.D.; Wiltzius, J.J.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 2005, 7(4), 301-311.
[http://dx.doi.org/10.1016/j.ccr.2005.03.003] [PMID: 15837620]

Lindberg, J.M.; Newhook, T.E.; Adair, S.J.; Walters, D.M.; Kim, A.J.; Stelow, E.B.; Parsons, J.T.; Bauer, T.W. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Neoplasia, 2014, 16(7), 562-571.
[http://dx.doi.org/10.1016/j.neo.2014.06.004] [PMID: 25117978]

Liu, Q.; Yu, S.; Zhao, W.; Qin, S.; Chu, Q.; Wu, K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol. Cancer, 2018, 17(1), 53.
[http://dx.doi.org/10.1186/s12943-018-0793-1] [PMID: 29455669]

López, R.; Méndez, C.M.; Fernández, M.J.; Reinoso, C.R.; Aldana, G.Q.; Fernández, M.S. DE LA Cámara Gómez, J.; López, M.R.; Vázquez, M.R.; Folgar, S.C. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). Anticancer Res., 2013, 33(2), 717-723.
[PMID: 23393373]

Luedke, E.; Jaime-Ramirez, A.C.; Bhave, N.; Carson, W.E., III Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation. J. Immunother., 2012, 35(5), 367-373.
[http://dx.doi.org/10.1097/CJI.0b013e3182562d76] [PMID: 22576341]

Maliakal, P.; Ledford, A. Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. Exp. Ther. Med., 2010, 1(2), 307-311.
[http://dx.doi.org/10.3892/etm_00000047] [PMID: 22993543]

Maruyama, I.N. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cells, 2014, 3(2), 304-330.
[http://dx.doi.org/10.3390/cells3020304] [PMID: 24758840]

Maurel, J.; Martin-Richard, M.; Conill, C.; Sánchez, M.; Petriz, L.; Ginès, A.; Miquel, R.; Gallego, R.; Cajal, R.; Ayuso, C.; Navarro, S.; Marmol, M.; Nadal, C.; Augé, J.M.; Fernández-Cruz, L.; Gascón, P. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66(5), 1391-1398.
[http://dx.doi.org/10.1016/j.ijrobp.2006.07.008] [PMID: 16965868]

McMichael, E.L.; Jaime-Ramirez, A.C.; Guenterberg, K.D.; Luedke, E.; Atwal, L.S.; Campbell, A.R.; Hu, Z.; Tatum, A.S.; Kondadasula, S.V.; Mo, X.; Tridandapani, S.; Bloomston, M.; Ellison, E.C.; Williams, T.M.; Bekaii-Saab, T.; Carson, W.E., III IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. Clin. Cancer Res., 2017, 23(2), 489-502.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0004] [PMID: 27435400]

Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol., 2006, 33(4), 369-385.
[http://dx.doi.org/10.1053/j.seminoncol.2006.04.003] [PMID: 16890793]

Milano, G.; Spano, J.P.; Leyland-Jones, B. EGFR-targeting drugs in combination with cytotoxic agents: From bench to bedside, a contrasted reality. Br. J. Cancer, 2008, 99(1), 1-5.
[http://dx.doi.org/10.1038/sj.bjc.6604373] [PMID: 18506149]

Modjtahedi, H.; Cho, B.C.; Michel, M.C.; Solca, F. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch. Pharmacol., 2014, 387(6), 505-521.
[http://dx.doi.org/10.1007/s00210-014-0967-3] [PMID: 24643470]

Mohammed, A.; Janakiram, N.B.; Li, Q.; Madka, V.; Ely, M.; Lightfoot, S.; Crawford, H.; Steele, V.E.; Rao, C.V. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev. Res. (Phila.), 2010, 3(11), 1417-1426.
[http://dx.doi.org/10.1158/1940-6207.CAPR-10-0038] [PMID: 21084261]

Montano, R.; Khan, N.; Hou, H.; Seigne, J.; Ernstoff, M.S.; Lewis, L.D.; Eastman, A. Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. Oncotarget, 2017, 8(40), 67754-67768.
[http://dx.doi.org/10.18632/oncotarget.18834] [PMID: 28978069]

Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. National cancer institute of canada clinical trials group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25(15), 1960-1966.
[http://dx.doi.org/10.1200/JCO.2006.07.9525] [PMID: 17452677]

Nie, W.; Tang, L.; Zhang, H.; Shao, J.; Wang, Y.; Chen, L.; Li, D.; Guan, X. Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. Int. J. Oncol, 2012, 40(6), 1763-1769.
[PMID: 22307557]

O’Keefe, E.; Battin, T.; Payne, R., Jr Epidermal growth factor receptor in human epidermal cells: Direct demonstration in cultured cells. J. Invest. Dermatol., 1982, 78(6), 482-487.
[http://dx.doi.org/10.1111/1523-1747.ep12510246] [PMID: 6177800]

Ogata, M.; Satake, H.; Ogata, T.; Imai, Y.; Hatachi, Y.; Yasui, H. No Correlation between KRAS status and advanced pancreatic adenocarcinoma survival. Cancer Clin. Oncol., 2017, 6
[http://dx.doi.org/10.5539/cco.v6n2p45]

Oh, D.Y.; Lee, K.W.; Lee, K.H.; Sohn, C.H.; Park, Y.S.; Zang, D.Y.; Ryoo, H.M.; Song, H.S.; Kim, J.S.; Kang, H.J.; Kim, B.S.; Bang, Y.J. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest. New Drugs, 2012, 30(3), 1164-1174.
[http://dx.doi.org/10.1007/s10637-011-9651-3] [PMID: 21404106]

Okusaka, T.; Furuse, J.; Funakoshi, A.; Ioka, T.; Yamao, K.; Ohkawa, S.; Boku, N.; Komatsu, Y.; Nakamori, S.; Iguchi, H.; Ito, T.; Nakagawa, K.; Nakachi, K. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci., 2011, 102(2), 425-431.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01810.x] [PMID: 21175992]

Philip, P.A.; Benedetti, J.; Corless, C.L.; Wong, R.; O’Reilly, E.M.; Flynn, P.J.; Rowland, K.M.; Atkins, J.N.; Mirtsching, B.C.; Rivkin, S.E.; Khorana, A.A.; Goldman, B.; Fenoglio-Preiser, C.M.; Abbruzzese, J.L.; Blanke, C.D. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol., 2010, 28(22), 3605-3610.
[http://dx.doi.org/10.1200/JCO.2009.25.7550] [PMID: 20606093]

Pino, M.S.; Shrader, M.; Baker, C.H.; Cognetti, F.; Xiong, H.Q.; Abbruzzese, J.L.; McConkey, D.J. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res., 2006, 66(7), 3802-3812.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3753] [PMID: 16585207]

Porterfield, BW DT; Patnaik, A; Rowinsky, E; Huberman, M; Clinebell, T Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial. J. Pancreas (Online), 2007, 2007;8(1), 4-15.

Propper, D.; Davidenko, I.; Bridgewater, J.; Kupcinskas, L.; Fittipaldo, A.; Hillenbach, C.; Klughammer, B.; Ducreux, M. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann. Oncol., 2014, 25(7), 1384-1390.
[http://dx.doi.org/10.1093/annonc/mdu176] [PMID: 24827134]

Pryczynicz, A.; Guzińska-Ustymowicz, K.; Kemona, A.; Czyzewska, J. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res, 2008, 28(2B), 1399-1404.
[PMID: 18505086]

Puleo, F.; Maréchal, R.; Demetter, P.; Bali, M.A.; Calomme, A.; Closset, J.; Bachet, J.B.; Deviere, J.; Van Laethem, J.L. New challenges in perioperative management of pancreatic cancer. World J. Gastroenterol., 2015, 21(8), 2281-2293.
[http://dx.doi.org/10.3748/wjg.v21.i8.2281] [PMID: 25741134]

Qing, L.; Qing, W. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer. Minerva Chir., 2018, 73(5), 488-496.
[http://dx.doi.org/10.23736/S0026-4733.18.07512-0] [PMID: 29397631]

Rayego-Mateos, S.; Rodrigues-Diez, R.; Morgado-Pascual, J.L.; Valentijn, F.; Valdivielso, J.M.; Goldschmeding, R.; Ruiz-Ortega, M. Role of Epidermal Growth Factor Receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm., 2018, 20188739473
[http://dx.doi.org/10.1155/2018/8739473] [PMID: 30670929]

Renouf, D.J.; Tang, P.A.; Hedley, D.; Chen, E.; Kamel-Reid, S.; Tsao, M.S.; Tran-Thanh, D.; Gill, S.; Dhani, N.; Au, H.J.; Wang, L.; Moore, M.J. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur. J. Cancer, 2014, 50(11), 1909-1915.
[http://dx.doi.org/10.1016/j.ejca.2014.04.008] [PMID: 24857345]

Ritter, C.A.; Arteaga, C.L. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin. Oncol., 2003, 30(1)(Suppl. 1), 3-11.
[http://dx.doi.org/10.1053/sonc.2003.50027] [PMID: 12644979]

Saif, M.W. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin. Adv. Hematol. Oncol., 2008, 6, 191-199.

Sandler, A.B. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park), 2006, 20(5)(Suppl. 2), 35-40.
[PMID: 16736981]

Schultheis, B.; Reuter, D.; Ebert, M.P.; Siveke, J.; Kerkhoff, A.; Berdel, W.E.; Hofheinz, R.; Behringer, D.M.; Schmidt, W.E.; Goker, E.; De Dosso, S.; Kneba, M.; Yalcin, S.; Overkamp, F.; Schlegel, F.; Dommach, M.; Rohrberg, R.; Steinmetz, T.; Bulitta, M.; Strumberg, D. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann. Oncol., 2017, 28(10), 2429-2435.
[http://dx.doi.org/10.1093/annonc/mdx343] [PMID: 28961832]

Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16(1), 15-31.
[http://dx.doi.org/10.1517/14728222.2011.648617] [PMID: 22239438]

Shin, J.U.; Park, J.H.; Cho, B.C.; Lee, J.H. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Dermatology (Basel), 2012, 225(2), 135-140.
[http://dx.doi.org/10.1159/000342203] [PMID: 23006507]

Shin, S.; Park, C.M.; Kwon, H.; Lee, K-H. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer, 2016, 16, 443-443.
[http://dx.doi.org/10.1186/s12885-016-2482-z] [PMID: 27400734]

Strumberg, D.; Schultheis, B.; Ebert, M.P.; Kerkhoff, A.; Hofheinz, R.D.; Behringer, D.M.; Schmidt, W.E.; Goker, E.; Dosso, S.D.; Kneba, M.; Yalcin, S.; Overkamp, F.; Schlegel, F.; Dommach, M.; Rohrberg, R.; Steinmetz, T.; Reuter, D.; Bach, F. Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC). J. Clin. Oncol., 2013, 31, 4009-4009.

Strumberg, D.; Schultheis, B.; Scheulen, M.E.; Hilger, R.A.; Krauss, J.; Marschner, N.; Lordick, F.; Bach, F.; Reuter, D.; Edler, L.; Mross, K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest. New Drugs, 2012, 30(3), 1138-1143.
[http://dx.doi.org/10.1007/s10637-010-9619-8] [PMID: 21170759]

Su, D.; Jiao, S.C.; Wang, L.J.; Shi, W.W.; Long, Y.Y.; Li, J.; Bai, L. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol., 2014, 35(3), 2313-2318.
[http://dx.doi.org/10.1007/s13277-013-1306-x] [PMID: 24142531]

Tabernero, J.; Kunzmann, V.; Scheithauer, W.; Reni, M.; Shiansong Li, J.; Ferrara, S.; Djazouli, K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: A subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets Ther., 2017, 10, 591-596.
[http://dx.doi.org/10.2147/OTT.S124097] [PMID: 28203092]

Tanaka, T.; Kaida, T.; Yokoi, K.; Ishii, S.; Nishizawa, N.; Kawamata, H.; Katoh, H.; Sato, T.; Nakamura, T.; Watanabe, M.; Yamashita, K. Critical relevance of genomic gains of PRL-3/EGFR/cmyc pathway genes in liver metastasis of colorectal cancer. Oncol. Lett., 2019, 17(1), 1257-1266.
[PMID: 30655893]

Thomas, G.; Chardès, T.; Gaborit, N.; Mollevi, C.; Leconet, W.; Robert, B.; Radosevic-Robin, N.; Penault-Llorca, F.; Gongora, C.; Colombo, P.E.; Lazrek, Y.; Bras-Goncalves, R.; Savina, A.; Azria, D.; Bazin, H.; Pèlegrin, A.; Larbouret, C. HER3 as biomarker and therapeutic target in pancreatic cancer: New insights in pertuzumab therapy in preclinical models. Oncotarget, 2014, 5(16), 7138-7148.
[http://dx.doi.org/10.18632/oncotarget.2231] [PMID: 25216528]

Tsujii, T.; Ogaki, T.; Nakae, K.; Imai, K.; Kise, D.; Tada, S.; Ueda, H.; Moriyama, M. Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody. J. Pharm. Health Care Sci., 2016, 2, 23-23.
[http://dx.doi.org/10.1186/s40780-016-0060-9] [PMID: 27688901]

Van Cutsem, E.; Vervenne, W.L.; Bennouna, J.; Humblet, Y.; Gill, S.; Van Laethem, J.L.; Verslype, C.; Scheithauer, W.; Shang, A.; Cosaert, J.; Moore, M.J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol., 2009, 27(13), 2231-2237.
[http://dx.doi.org/10.1200/JCO.2008.20.0238] [PMID: 19307500]

Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, R.K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med., 2013, 369(18), 1691-1703.
[http://dx.doi.org/10.1056/NEJMoa1304369] [PMID: 24131140]

Wee, P.; Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel), 2017, 9(5), 9.
[PMID: 28513565]

Westover, D.; Zugazagoitia, J.; Cho, B.C.; Lovly, C.M.; Paz-Ares, L. Mechanisms of acquired resistance to first- and secondgeneration EGFR tyrosine kinase inhibitors. Ann. Oncol, 2018, 29(suppl_1), i10-i19.
[http://dx.doi.org/10.1093/annonc/mdx703] [PMID: 29462254]

Xiong, H.Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R.A.; Deutsch, J.; Needle, M.; Abbruzzese, J.L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J. Clin. Oncol., 2004, 22(13), 2610-2616.
[http://dx.doi.org/10.1200/JCO.2004.12.040] [PMID: 15226328]

Yara Abdou, S.C.F.; Yehuda, Z. Patt, Christine Gan, Fa-Chyi Lee: Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer. J. Clin. Oncol., 2016, 35(15-Suppl), 2017, e15781.

Zhang, G.; Basti, S.; Jampol, L.M. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: Case reports and a review of literature. Cornea, 2007, 26(7), 858-860.
[http://dx.doi.org/10.1097/ICO.0b013e318064584a] [PMID: 17667622]

Zhou, C.; Zhu, L.; Ji, J.; Ding, F.; Wang, C.; Cai, Q.; Yu, Y.; Zhu, Z.; Zhang, J. EGFR high expression, but not KRAS status, predicts sensitivity of pancreatic cancer cells to nimotuzumab treatment in vivo. Curr. Cancer Drug Targets, 2017, 17(1), 89-97.
[http://dx.doi.org/10.2174/1568009616666161013101657] [PMID: 27739365]

Zhou, X.; Zheng, M; Chen, F; Zhu, Y; Yong, W; Lin, H; Sun, Y; Han, X Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anatomical Record (Hoboken, NJ : 2007), 2009, 292, 1122-1127.
[http://dx.doi.org/10.1002/ar.20938]